To install click the Add extension button. That's it.

The source code for the WIKI 2 extension is being checked by specialists of the Mozilla Foundation, Google, and Apple. You could also do it yourself at any point in time.

4,5
Kelly Slayton
Congratulations on this excellent venture… what a great idea!
Alexander Grigorievskiy
I use WIKI 2 every day and almost forgot how the original Wikipedia looks like.
Live Statistics
English Articles
Improved in 24 Hours
Added in 24 Hours
What we do. Every page goes through several hundred of perfecting techniques; in live mode. Quite the same Wikipedia. Just better.
.
Leo
Newton
Brights
Milds

From Wikipedia, the free encyclopedia

Belatacept
Clinical data
Trade namesNulojix
AHFS/Drugs.comMonograph
MedlinePlusa606016
License data
Pregnancy
category
  • AU: C
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: WARNING[1]Rx-only
  • EU: Rx-only
Identifiers
CAS Number
DrugBank
ChemSpider
  • None
UNII
KEGG
 ☒NcheckY (what is this?)  (verify)

Belatacept, sold under the brand name Nulojix, is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4,[2] which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. It is intended to provide extended graft and transplant[3] survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. It differs from abatacept (Orencia) by only two amino acids.[medical citation needed]

Belatacept was developed by Bristol-Myers-Squibb and approved by the U.S. Food and Drug Administration (FDA) on June 15, 2011.[4]

References

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. ^ "Healthvalue.net: CTLA-4 Strategies". Archived from the original on 5 December 2008. Retrieved 2008-10-24.
  3. ^ Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, et al. (January 2016). "Belatacept and Long-Term Outcomes in Kidney Transplantation". The New England Journal of Medicine. 374 (4): 333–43. doi:10.1056/NEJMoa1506027. hdl:2445/178537. PMID 26816011. S2CID 35661528.
  4. ^ "FDA approves Nulojix for kidney transplant patients" (Press release). U.S. Food and Drug Administration. 2011-06-15. Archived from the original on 19 June 2011. Retrieved 2011-06-16.

External links

  • "Belatacept". Drug Information Portal. U.S. National Library of Medicine.
This page was last edited on 2 December 2023, at 07:01
Basis of this page is in Wikipedia. Text is available under the CC BY-SA 3.0 Unported License. Non-text media are available under their specified licenses. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. WIKI 2 is an independent company and has no affiliation with Wikimedia Foundation.